Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM)

Barclays PLC grew its position in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 3,661,933.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 549,305 shares of the company’s stock after buying an additional 549,290 shares during the quarter. Barclays PLC owned approximately 1.32% of Carisma Therapeutics worth $539,000 at the end of the most recent quarter.

Separately, Wexford Capital LP boosted its stake in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.44 on Friday. The firm has a market cap of $18.40 million, a price-to-earnings ratio of -0.28 and a beta of 1.56. Carisma Therapeutics, Inc. has a 1 year low of $0.38 and a 1 year high of $2.77. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The business has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.90.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. As a group, sell-side analysts predict that Carisma Therapeutics, Inc. will post -1.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CARM. Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Evercore ISI reiterated an “in-line” rating and set a $0.70 price target (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $10.00 to $1.00 in a research note on Thursday, December 12th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.